$250 | Single User
$500 | Site License
$750 | Global License

GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
[Report Updated: 12-10-2018]

Published by Global Data: 12 Oct 2018 | 224563 | In Stock
Related Topics: GlaxoSmithKline , Healthcare

Introduction

Summary

GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents
for GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 12-10-2018]

  • Table of Contents

    Table of Contents 3

    List of Tables 11

    List of Figures 16

    GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

    GlaxoSmithKline Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 18

    GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

    GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 20

    GlaxoSmithKline Plc, Medical Devices Deals, 2012 to YTD 2018 22

    GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 23

    GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deal Details 46

    Asset Purchase 46

    ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 46

    ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 48

    GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis 49

    GlaxoSmithKline Acquires Vaccines Business of Novartis for up to USD7.1 Billion 51

    Novartis India to Sell Its OTC Division to GlaxoSmithKline Consumer 53

    ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 54

    Stiefel Labs Acquires WBI-1001 From Welichem Biotech For US Million 55

    Venture Financing 57

    Gotham Therapeutics Raises USD54 Million in Series A Financing 57

    Sitryx Therapeutics Raises USD30 Million in Series A Financing 59

    Morphic Therapeutic Raises USD80 Million in Series B Financing 61

    Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 63

    Nimbus Therapeutics Raises USD65 Million in Financing 65

    Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 67

    Constellation Pharma Raises USD100 Million in Financing 69

    Macrolide Pharma Raises USD20 Million in Venture Financing 71

    Pandion Therapeutics Raises USD58 Million in Series A Finanicng 72

    Atox Bio Raises USD30 Million in Financing 73

    Palleon Pharma Raises USD47.6 Million in Series A Financing 75

    eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 76

    Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 78

    TP Therapeutics Raises USD45 Million in Series C Financing 80

    Pulmocide Raises USD30.4 Million in Series B Financing 81

    Spero Therapeutics Raises USD51.7 Million in Series C Financing 83

    Tioma Therapeutics Raises USD86 Million in Series A Financing 85

    Second Genome Raises USD8.4 Million in Extended Series B Financing 86

    Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 87

    PDI Therapeutics to Raise up to USD10 Million in Series A Venture Financing 89

    Spero Therapeutics Raises USD30 Million in Series B Funding 90

    Mission Therapeutics Raises USD85.7 Million in Financing Round 92

    Nkarta Raises Funds through Venture Financing 94

    Effector Therapeutics Raises USD40 Million in Series B Venture Financing 95

    Navitor Pharma Raises USD33 Million in Series B Financing 97

    Constellation Pharma Raises USD55 Million Financing 99

    True North Therapeutics Raises USD40 Million in Series C Financing 101

    Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 103

    Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 104

    Atreca Raises USD56 Million in Series A Financing 105

    Puridify Raises USD3.4 Million in Series A Financing 107

    Decibel Therapeutics Raises USD52 Million in Series A Financing Round 108

    Asceneuron Raises USD30.6 Million in Series A Financing 109

    Gladius Pharma Raises USD3.3 Million in Series A Financing 111

    Atopix Therapeutics Raises Additional Funds through Venture Financing 112

    Adrenergics Raises up to USD10 Million in Series A Financing 113

    CadheRx Therapeutics Raises up to USD10 Million in Series A Financing 114

    Calporta Therapeutics Raises up to USD10 Million in Series A Financing 115

    Spero Therapeutics Raises USD30 Million in Extended Series A Financing 116

    PsiOxus Therapeutics Raises USD39.2 Million in Series C Financing 118

    CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 120

    CRISPR Therapeutics Raises USD29 Million in Series B Financing 122

    ZappRx Raises USD5.6 Million in Series A Financing 124

    Thrasos Therapeutics Raises USD21 Million in Series D Financing 125

    Nimbus Therapeutics Raises USD43 Million in Series B Financing 127

    Macrolide Pharma Raises USD22 Million in Series A Financing 129

    Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 130

    Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 132

    Atopix Therapeutics Raises Funds through Extended Series A Financing 134

    Silarus Therapeutics to Raise up to USD10 Million in Series A Venture Financing 135

    Thyritope Biosciences to Raise up to USD10 Million in Series A Venture Financing 136

    Atox Bio Raises up to USD23 Million in Series E Venture Financing 137

    Navitor Pharma Raises USD24 Million in Series A Financing 138

    True North Therapeutics Raises USD22 Million in Series A Venture Financing 140

    Puridify Raises USD1.43 Million in Seed Funding 142

    Principia Biopharma Raises US Million In Series B Venture Financing 143

    Spero Therapeutics Raises USD3 Million in Series A Venture Financing 145

    Alios BioPharma Raises US Million In Series B Venture Financing 146

    RuiYi Raises US Million In Series B Financing 147

    HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 149

    VHsquared Secures Series A Funding Round 150

    Sitari Pharma Raises US Million In Series A Financing 151

    Mission Therapeutics Raises US Million In Series B Financing 152

    Aileron Therapeutics Raises US Million In Series E Financing 154

    F-Star Alpha Raises US Million In Series A Financing 156

    iPierian Raises US Million In Series A Venture Financing 158

    Effector Therapeutics Raises US Million In Series A Financing 160

    Progenitor Labs Raises US.8 Million In Seed Financing 162

    Aileron Raises US Million In Extended Series D Financing 163

    NeRRe Therapeutics Raises US Million In Series A Financing 165

    River Vision Development Raises US Million In Series A Financing 166

    Bicycle Therapeutics Raises US Million In Venture Financing 167

    Applied Genetic Technologies Raises US.5 Million In Series B Financing 169

    HTG Molecular Diagnostics Raises US.5 Million In Series E Financing 171

    Thrasos Therapeutics Raises US Million In Venture Financing 172

    SR One Plans To Invest In Biotechnology Company 174

    Genocea Biosciences Raises US Million In Series C Financing 175

    Principia Biopharma Raises Additional US Million In Series A Financing 177

    PsiOxus Therapeutics Raises Additional US Million In Series B Financing 179

    RaNA Therapeutics Raises Additional US Million In Series A Financing 181

    Partnerships 183

    GlaxoSmithKline and 23andMe Enter into Collaboration Agreement 183

    MolMed Enters into Development Agreement with GlaxoSmithKline 185

    Cloud Pharma Enters into Partnership with GlaxoSmithKline 186

    Kymera Therapeutics Enters into Agreement with GlaxoSmithKline 187

    National Institute for Health Research Enters into Research Agreement with GlaxoSmithKline 188

    Owlstone Medical Enters into Co-Development Agreement with GlaxoSmithKline 189

    Plasticell Enters into Agreement with GlaxoSmithKline 190

    AbCellera Biologics Enters into Research Partnership with GlaxosmithKline 191

    Oklahoma Medical Research Foundation Enters into Agreement with GlaxoSmithKline 192

    Exscientia Enters into Partnership with GlaxoSmithKline (GSK) 193

    Aseptic Technologies Enters into Agreement with MedCision 194

    Warp Drive Bio Enters to Agreement with GlaxoSmithKline 195

    Telo Therapeutics Enters into Research Agreement with GlaxoSmithKline 196

    GlaxoSmithKline Biologicals Enters into Option Agreement with Aridis Pharma 197

    Puridify Enters into Agreement with GlaxoSmithKline 198

    Fimbrion Therapeutics Enters into Co-Development Agreement with GlaxoSmithKline 199

    GlaxoSmithKline Enters into Co-Development Agreement with University of Leicester 200

    GlaxoSmithKline Forms Joint Venture with Avalon Ventures 201

    GlaxoSmithKline Enters into Agreement with Miltenyi Biotec 202

    VBI Vaccines Enters into Research Agreement with GlaxoSmithKline Biologicals 203

    Valneva Enters into R&D Agreement with GlaxoSmithKline 204

    ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 205

    GlaxoSmithKline Enters into Research Agreement with NIAID 206

    GlaxoSmithKline Forms Iron Horse Therapeutics with Avalon Ventures 207

    GlaxoSmithKline Partners with Merck 208

    Pfizer Enters into Agreement with GlaxoSmithKline 209

    UC San Francisco Enters into Research Agreement with GlaxoSmithKline 210

    MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 211

    GlaxoSmithKline Enters into Partnership with Francis Crick Institute 212

    University of North Carolina Forms Joint Venture with GlaxoSmithKline 213

    Cold Spring Harbor Labs Enters into Co-Development Agreement with GlaxoSmithKline 214

    MolMed Enters into Agreement with GlaxoSmithKline 215

    Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 216

    GlaxoSmithKline, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation Enter into Co-Development Agreement 218

    ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 219

    Bioversys Enters into Agreement with GlaxoSmithKline and University of Lille 220

    Metabolon Enters Into Agreement With GlaxoSmithKline For Metabolomic Profiling Services 221

    GlaxoSmithKline Enters Into Agreement With University of Texas MD Anderson Cancer Center For Immunotherapy Drugs 222

    BioRap Enters into Agreement with GlaxoSmithKline 223

    GlaxoSmithKline Enters into Partnership with Yale University 224

    Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 225

    GlaxoSmithKline Forms Joint Venture With Biological E 226

    ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 227

    GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 228

    GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 229

    GlaxoSmithKline Expands its Partnership with Adimab 230

    GlaxoSmithKline Plans To Partner With Chinese Companies 231

    GlaxoSmithKline Enters Into Co-Development Agreement With Institute of Chemical Engineering And Sciences 232

    Eddingpharm Enters Into Distribution Agreement With GlaxoSmithKline For Tykerb 233

    AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 234

    Proteologics And GlaxoSmithKline Extend Their Research Agreement 235

    Hospital for Sick Children Enters Into Research Agreement With GlaxoSmithKline To Discover Treatment For Cystic Fibrosis 236

    Vanderbilt University Enters Into Research Agreement With GlaxoSmithKline For Obesity Drug 237

    Priaxon Enters Into Co-Development Agreement With GlaxoSmithKline For Small Molecule Modulators Of PPIs 238

    Chroma Therapeutics Expands Co-Development Agreement With GlaxoSmithKline 239

    GlycoVaxyn Enters Into Co-Development Agreement With GlaxoSmithKline For Bacterial Vaccines 240

    Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 241

    GlaxoSmithKline Enters Into Agreement With Imagine Institute To Discover New Drugs For Netherton Syndrome 242

    Chiromics Enters Into Drug Discovery Agreement With GlaxoSmithKline 243

    Aeras Enters Into R&D Agreement With GlaxoSmithKline Vaccines To Develop Tuberculosis Vaccine 244

    GlaxoSmithKline Enters Into Co-Development Agreement With University of Cambridge 245

    PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 246

    Daiichi Sankyo And GlaxoSmithKline Form Joint Venture In Japan 247

    Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 248

    Desitin Arzneimittel Enters Into Co-Promotion Agreement With GlaxoSmithKline For Elontril 249

    GlaxoSmithKline Enters Into Co-Development Agreement With Yale University 250

    Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 251

    Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 252

    GlaxoSmithKline Enters Into Co-Development Agreement With University of Dundee 253

    Angiochem Enters Into Co-Development Agreement With GlaxoSmithKline 254

    GlaxoSmithKline Enters Into Agreement With Coland Holdings 255

    GlaxoSmithKline Enters Into Co-Development Agreement With Sienna Biotec 256

    Eddingpharm Enters Distribution Agreement With GlaxoSmithKline For Relafen 257

    Licensing Agreements 258

    Boston Pharma Enters into Licensing Agreement with GlaxoSmithKline 258

    GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 259

    Zai Lab Enters into Licensing agreement with GlaxoSmithKline 260

    GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 261

    GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 262

    Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 263

    Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 264

    Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 265

    GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 266

    Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 267

    GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 268

    Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 269

    Codexis Enters into Licensing Agreement with GlaxoSmithKline for CodeEvolver Protein Engineering Platform 270

    Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 272

    GlaxoSmithKline Enters into Licensing Agreement with Adaptimmune Therapeutics 273

    GlaxoSmithKline Exercises Licensing Agreement with Adaptimmune 274

    GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 276

    GlaxoSmithKline Enters Into Licensing Agreement With Adimab 277

    Immunocore Enters Into Licensing Agreement With GSK For ImmTACs 278

    MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 279

    GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 281

    GlaxoSmithKline Enters Into Licensing Agreement With University of Texas MD Anderson Cancer Center For Antibodies 282

    NeRRe Therapeutics Receives Neurokinin Receptor Antagonists from GlaxoSmithKline 283

    Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 284

    Liquidia Technologies Exercises Option for Licensing Agreement with GlaxoSmithKline 286

    GlaxoSmithKline Enters into Licensing Agreement with Pelago Bioscience for CETSA 287

    Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 288

    Medicines Patent Pool Extends Licensing Agreement with ViiV Healthcare 289

    ViiV Healthcare Enters Into Licensing Agreement With Medicines Patent Pool For Epzicom 290

    GlaxoSmithKline Enters Into Licensing Agreement With Alacris Theranostics For ModCell System 291

    ViiV Healthcare Announces Licensing Agreement For Celsentri 292

    GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 293

    Equity Offering 294

    Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 294

    Theravance Biopharma Raises USD23 Million in Private Placement of Shares 296

    Amicus Therapeutics Completes Private Placement Of Securities For US Million 297

    Theravance Completes Private Placement Of Shares For US3 Million 298

    ChemoCentryx Raises USD7 million in Private Placement of Shares 299

    Debt Offering 300

    GlaxoSmithKline Raises USD1.19 Billion in Public Offering of 1.25% Bonds Due 2026 300

    GlaxoSmithKline Raises USD897.1 Million in Public Offering of Bonds Due 2020 301

    GlaxoSmithKline Raises USD897.1 Million in Public Offering of 1.75% Bonds Due 2030 302

    GlaxoSmithKline Raises USD1.25 Billion in Public Offering of 3.375% Bonds Due 2023 303

    GlaxoSmithKline Raises USD0.75 Billion in Public Offering of Bonds Due 2021 304

    GlaxoSmithKline Raises USD1.75 Billion in Public Offering of 3.875% Bonds Due 2028 305

    GlaxoSmithKline Raises USD1.25 Billion in Public Offering of 3.125% Bonds Due 2021 307

    GlaxoSmithKline Raises USD1 Billion in Public Offering of 3.625% Bonds Due 2025 309

    GlaxoSmithKline Raises USD832.8 Million in Public Offering of Bonds Due 2026 311

    GlaxoSmithKline Raises USD1,428 Million in Public Offering of Bonds Due 2020 312

    GlaxoSmithKline Completes Public Offering Of 0.75% Senior Notes Due 2015 For US,000 Million 313

    GlaxoSmithKline Completes Public Offering Of 1.5% Senior Notes Due 2017 For US,000 Million 314

    GlaxoSmithKline Completes Public Offering Of 2.85% Senior Notes Due 2022 For US,000 Million 315

    Asset Transactions 316

    Dermavant Sciences Acquires Rights of Tapinarof from GlaxoSmithKline for USD331 Million 316

    Orchard Therapeutics Acquires Rare Disease Gene Therapy Portfolio from GlaxoSmithKline 317

    GlaxoSmithKline Plans to Sell its Ulverston Plant 318

    Emergent Biosolutions Acquires Raxibacumab from GSK 319

    Avara Pharma to Acquire Consumer Healthcare Manufacturing Facility from GlaxoSmithKline 321

    GlaxoSmithKline Plans to Sell its Non-Core brands 322

    Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 323

    Oncodesign Acquires Francois Hyafil Research Centre from GlaxoSmithKline 324

    Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 325

    Novartis Pharma Acquires Rights to Ofatumumab for Auto-Immune Indications from GlaxoSmithKline for up to USD1 Billion 326

    Almirall Acquires Rights to Veltin and Altabax from Stiefel 327

    Interbrands Acquires Europharm from GSK 328

    Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 329

    Sun Pharma Acquires Opiates Business in Australia from GlaxoSmithKline 330

    Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 331

    Insulet Acquires Distribution Rights from GlaxoSmithKline 332

    Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 333

    Roivant Acquires SB742457 from GlaxoSmithKline 335

    Dr Reddy's Labs Acquires Habitrol from Novartis Consumer Health 336

    Axovant Sciences Acquires Rights to RVT-101 from Glaxo Group and GlaxoSmithKline Intellectual 337

    Pernix Therapeutics Completes Acquisition of Treximet Tablets For Migraine From GlaxoSmithKline 338

    Suntory Beverage Acquires Lucozade and Ribena Brands from GlaxoSmithKline for USD2.1 Billion 340

    Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 342

    Aqua Pharma Acquires US Rights To Verdeso Foam From Stiefel 344

    Renaissance Acquisition To Acquire Six Dermatology And Three Anti-Viral Products From GSK 345

    Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 347

    Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For US7 Million 348

    Merz Pharma Acquires Onmel From Stiefel Labs 351

    Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 352

    Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US4 Million 353

    Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For US3 Million 355

    Prestige Brands Completes Acquisition Of 17 OTC Healthcare Brands From GlaxoSmithKline For US0 Million 357

    Acquisition 360

    Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 360

    GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 362

    GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 364

    GlaxoSmithKline Acquires Additional 26% of stake in Glaxo Saudi Arabia 365

    MediPal Plans to Acquire 22% Stake in JCR Pharma from Glaxo Group for USD189.7 Million 366

    Pacific Biosciences May Sell Itself 367

    GlaxoSmithKline Acquires Remaining Stake in GlycoVaxyn for USD190 Million 368

    GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 370

    AstraZeneca May Acquire Ariad Pharma 371

    GlaxoSmithKline Acquires Remaining 30% Stake In Consumer Healthcare Business For US.6 Million 373

    GlaxoSmithKline Completes Acquisition Of Additional 24.3% Stake In Indian Arm GlaxoSmithKline Pharma For US.03 Billion 374

    GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For US6.5 Million 376

    Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 378

    GlaxoSmithKline Acquires Okairos For US5 Million 380

    GlaxoSmithKline And Avalon Ventures To Invest US5 Million In 10 Drug Discovery Startups 382

    GSK Increases Stake In Indian Arm GlaxoSmithKline Consumer Healthcare For US4 Million 383

    Takeda America Completes Acquisition Of LigoCyte Pharma For US Million 385

    GlaxoSmithKline Acquires Remaining 80.02% Stake In Cellzome, Proteomics Company, For US Million 387

    GlaxoSmithKline Completes Acquisition Of Human Genome Sciences For US.6 Billion 389

    GlaxoSmithKline Plans To Acquire BioMarin Pharma 392

    GlaxoSmithKline Plans To Acquire Turkey-based Pharma Company 393

    GlaxoSmithKline Plc - Key Competitors 394

    GlaxoSmithKline Plc - Key Employees 395

    GlaxoSmithKline Plc - Locations And Subsidiaries 396

    Head Office 396

    Other Locations & Subsidiaries 396

    Joint Venture 409

    Recent Developments 410

    Financial Announcements 410

    Jul 25, 2018: GSK delivers improvements in sales, margins and cash flow in Q2 2018 410

    Feb 07, 2018: GSK delivers improvements in sales, margins and cash flow in 2017 413

    Oct 25, 2017: GSK delivers Q3 sales of £7.8 billion, +4% AER, +2% CER 414

    Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group 426

    Apr 26, 2017: GSK delivers another quarter of continued progress 432

    Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 435

    Corporate Communications 451

    Aug 07, 2018: Iain Mackay appointed GSK Chief Financial Officer 451

    Jun 12, 2018: GSK announces changes to Vaccines and Global Manufacturing & Supply leadership 452

    May 09, 2018: Simon Dingemans, Chief Financial Officer, to retire from GSK 453

    Apr 18, 2018: GlaxoSmithKline Names Kevin Sin as new Senior Vice President and Head of Worldwide Business Development for Research & Development 454

    Jan 09, 2018: Representative Director and President of GlaxoSmithKline Corporation Personnel notice 455

    Nov 08, 2017: Patrick Vallance, President, R&D, GSK to become UK Government's Chief Scientific Adviser 456

    Nov 08, 2017: Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK 457

    Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK 458

    Jul 21, 2017: GSK announces Board and Committee changes 459

    Jun 19, 2017: GSK confirms start date for Luke Miels 460

    Jun 05, 2017: Four innovations to tackle under-five deaths win US million Healthcare Innovation Award from GSK and Save the Children 461

    Apr 04, 2017: GSK responds to Cyclone Debbie 463

    Jan 20, 2017: Luke Miels will succeed Abbas Hussain as President, Global Pharmaceuticals, GSK 464

    Jan 19, 2017: Abbas Hussain to leave GSK 465

    Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 466

    Legal and Regulatory 467

    Sep 14, 2018: Second former Glaxosmithkline scientist pleads guilty to stealing trade secrets to benefit chinese pharmaceutical company 467

    Sep 03, 2018: Former GSK researcher admits plot to steal trade secrets 468

    Feb 23, 2018: GSK, Ministry of Economy, Trade and Industry "Superior Health and Good Management Act 2018 (White 500)" for 2 consecutive years certified 469

    Sep 19, 2017: GHJP Closes Two-Year FOIA Case Against Drug Manufacturer 470

    Government and Public Interest 471

    Oct 02, 2018: GSK updates policy for working with healthcare professionals 471

    Jul 25, 2018: Discovery of a new potential treatment for visceral leishmaniasis 472

    May 15, 2018: Aiming Low: Landmark study optimises steroid use in pregnancy 474

    Mar 19, 2018: The Pistoia Alliance Calls for Greater Life Sciences Collaboration to Build the ‘Lab of the Future’ 475

    Feb 20, 2018: Scientists find new antimalarial drug targets 476

    Nov 30, 2017: New HIV Prevention Trials Hold Promise for New Prevention Options for Women 477

    Nov 22, 2017: Common gastric acid medicine may target tuberculosis 478

    Jul 11, 2017: Shortcut Method in Drug Development 479

    Apr 27, 2017: Wellcome backs Dundee and GSK in neglected diseases drug quest 480

    Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis 481

    Product News 483

    12/11/2017: Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study 483

    12/11/2017: GSK presents promising new data for priority BCMA asset from its emerging Oncology pipeline at 59th ASH meeting 484

    12/05/2017: Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study 485

    11/10/2017: Adaptimmune Presents Study Design for Ongoing Anti-neoplastic NY-ESO SPEAR T-cell Clinical Trial at the Society for Immunotherapy of Cancer Annual Meeting 486

    11/09/2017: NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune’s SPEAR T-Cell Therapy 487

    11/02/2017: GSK's investigational BCMA antibody-drug conjugate receives Breakthrough Therapy Designation from US FDA for relapsed and refractory multiple myeloma 488

    Oct 01, 2018: Theraflu PowerPods launches Pods For convenient cold and flu symptom relief 489

    09/12/2017: TGA approves MENVEO vaccine to help protect babies from two months old from meningococcal disease 490

    07/24/2018: GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK 492

    07/11/2017: Recall of MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular injection 493

    06/05/2017: Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology Annual Meeting 494

    06/02/2018: Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile 497

    05/26/2017: Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology Annual Meeting 499

    05/16/2018: Adaptimmune to Present Data from Study of NY-ESO SPEAR T-cells in Myxoid/Round Cell Liposarcoma at ASCO Annual Meeting 501

    05/04/2017: Epizyme Earns Million Milestone Payment from GlaxoSmithKline for Initiation of GLP Toxicology Studies with Novel Methyltransferase Inhibitor 502

    04/24/2017: PATH and GSK welcome progress toward RTS,S malaria vaccine pilot implementation with selection of countries 503

    03/24/2017: GSK Announces Availability of Menveo (meningococcal ACWY vaccine) 504

    03/15/2018: Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells 505

    Clinical Trials 506

    Jun 11, 2018: Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self-renewing, and Capable of Persistent Anti-Tumor Effects 506

    May 25, 2017: Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA (pembrolizumab) in Multiple Myeloma 508

    Other Significant Developments 509

    Jun 11, 2018: WuXi AppTec to test AI-generated compounds from Insilico Medicine 509

    Mar 23, 2018: GSK Update Regarding Pfizer Consumer Healthcare 510

    Dec 06, 2017: GSK welcomes launch of the UK Government’s Life Sciences Sector Deal 511

    Aug 30, 2017: GSK responds to UK Life Sciences Industrial Strategy 512

    Jul 19, 2017: GSK updates on UK manufacturing network 513

    Appendix 514

    Methodology 514

    About GlobalData 514

    Contact Us 514

    Disclaimer 514

List Of Tables
in GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 12-10-2018]

List of Tables

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 18

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

GlaxoSmithKline Plc, Deals By Therapy Area, 2012 to YTD 2018 20

GlaxoSmithKline Plc, Medical Devices Deals, 2012 to YTD 2018 22

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 23

ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 46

ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 48

GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis 49

GlaxoSmithKline Acquires Vaccines Business of Novartis for up to USD7.1 Billion 51

Novartis India to Sell Its OTC Division to GlaxoSmithKline Consumer 53

ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 54

Stiefel Labs Acquires WBI-1001 From Welichem Biotech For US Million 55

Gotham Therapeutics Raises USD54 Million in Series A Financing 57

Sitryx Therapeutics Raises USD30 Million in Series A Financing 59

Morphic Therapeutic Raises USD80 Million in Series B Financing 61

Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 63

Nimbus Therapeutics Raises USD65 Million in Financing 65

Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 67

Constellation Pharma Raises USD100 Million in Financing 69

Macrolide Pharma Raises USD20 Million in Venture Financing 71

Pandion Therapeutics Raises USD58 Million in Series A Finanicng 72

Atox Bio Raises USD30 Million in Financing 73

Palleon Pharma Raises USD47.6 Million in Series A Financing 75

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 76

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 78

TP Therapeutics Raises USD45 Million in Series C Financing 80

Pulmocide Raises USD30.4 Million in Series B Financing 81

Spero Therapeutics Raises USD51.7 Million in Series C Financing 83

Tioma Therapeutics Raises USD86 Million in Series A Financing 85

Second Genome Raises USD8.4 Million in Extended Series B Financing 86

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 87

PDI Therapeutics to Raise up to USD10 Million in Series A Venture Financing 89

Spero Therapeutics Raises USD30 Million in Series B Funding 90

Mission Therapeutics Raises USD85.7 Million in Financing Round 92

Nkarta Raises Funds through Venture Financing 94

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 95

Navitor Pharma Raises USD33 Million in Series B Financing 97

Constellation Pharma Raises USD55 Million Financing 99

True North Therapeutics Raises USD40 Million in Series C Financing 101

Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 103

Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 104

Atreca Raises USD56 Million in Series A Financing 105

Puridify Raises USD3.4 Million in Series A Financing 107

Decibel Therapeutics Raises USD52 Million in Series A Financing Round 108

Asceneuron Raises USD30.6 Million in Series A Financing 109

Gladius Pharma Raises USD3.3 Million in Series A Financing 111

Atopix Therapeutics Raises Additional Funds through Venture Financing 112

Adrenergics Raises up to USD10 Million in Series A Financing 113

CadheRx Therapeutics Raises up to USD10 Million in Series A Financing 114

Calporta Therapeutics Raises up to USD10 Million in Series A Financing 115

Spero Therapeutics Raises USD30 Million in Extended Series A Financing 116

PsiOxus Therapeutics Raises USD39.2 Million in Series C Financing 118

CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 120

CRISPR Therapeutics Raises USD29 Million in Series B Financing 122

ZappRx Raises USD5.6 Million in Series A Financing 124

Thrasos Therapeutics Raises USD21 Million in Series D Financing 125

Nimbus Therapeutics Raises USD43 Million in Series B Financing 127

Macrolide Pharma Raises USD22 Million in Series A Financing 129

Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 130

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 132

Atopix Therapeutics Raises Funds through Extended Series A Financing 134

Silarus Therapeutics to Raise up to USD10 Million in Series A Venture Financing 135

Thyritope Biosciences to Raise up to USD10 Million in Series A Venture Financing 136

Atox Bio Raises up to USD23 Million in Series E Venture Financing 137

Navitor Pharma Raises USD24 Million in Series A Financing 138

True North Therapeutics Raises USD22 Million in Series A Venture Financing 140

Puridify Raises USD1.43 Million in Seed Funding 142

Principia Biopharma Raises US Million In Series B Venture Financing 143

Spero Therapeutics Raises USD3 Million in Series A Venture Financing 145

Alios BioPharma Raises US Million In Series B Venture Financing 146

RuiYi Raises US Million In Series B Financing 147

HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 149

VHsquared Secures Series A Funding Round 150

Sitari Pharma Raises US Million In Series A Financing 151

Mission Therapeutics Raises US Million In Series B Financing 152

Aileron Therapeutics Raises US Million In Series E Financing 154

F-Star Alpha Raises US Million In Series A Financing 156

iPierian Raises US Million In Series A Venture Financing 158

Effector Therapeutics Raises US Million In Series A Financing 160

Progenitor Labs Raises US.8 Million In Seed Financing 162

Aileron Raises US Million In Extended Series D Financing 163

NeRRe Therapeutics Raises US Million In Series A Financing 165

River Vision Development Raises US Million In Series A Financing 166

Bicycle Therapeutics Raises US Million In Venture Financing 167

Applied Genetic Technologies Raises US.5 Million In Series B Financing 169

HTG Molecular Diagnostics Raises US.5 Million In Series E Financing 171

Thrasos Therapeutics Raises US Million In Venture Financing 172

SR One Plans To Invest In Biotechnology Company 174

Genocea Biosciences Raises US Million In Series C Financing 175

Principia Biopharma Raises Additional US Million In Series A Financing 177

PsiOxus Therapeutics Raises Additional US Million In Series B Financing 179

RaNA Therapeutics Raises Additional US Million In Series A Financing 181

GlaxoSmithKline and 23andMe Enter into Collaboration Agreement 183

MolMed Enters into Development Agreement with GlaxoSmithKline 185

Cloud Pharma Enters into Partnership with GlaxoSmithKline 186

Kymera Therapeutics Enters into Agreement with GlaxoSmithKline 187

National Institute for Health Research Enters into Research Agreement with GlaxoSmithKline 188

Owlstone Medical Enters into Co-Development Agreement with GlaxoSmithKline 189

Plasticell Enters into Agreement with GlaxoSmithKline 190

AbCellera Biologics Enters into Research Partnership with GlaxosmithKline 191

Oklahoma Medical Research Foundation Enters into Agreement with GlaxoSmithKline 192

Exscientia Enters into Partnership with GlaxoSmithKline (GSK) 193

Aseptic Technologies Enters into Agreement with MedCision 194

Warp Drive Bio Enters to Agreement with GlaxoSmithKline 195

Telo Therapeutics Enters into Research Agreement with GlaxoSmithKline 196

GlaxoSmithKline Biologicals Enters into Option Agreement with Aridis Pharma 197

Puridify Enters into Agreement with GlaxoSmithKline 198

Fimbrion Therapeutics Enters into Co-Development Agreement with GlaxoSmithKline 199

GlaxoSmithKline Enters into Co-Development Agreement with University of Leicester 200

GlaxoSmithKline Forms Joint Venture with Avalon Ventures 201

GlaxoSmithKline Enters into Agreement with Miltenyi Biotec 202

VBI Vaccines Enters into Research Agreement with GlaxoSmithKline Biologicals 203

Valneva Enters into R&D Agreement with GlaxoSmithKline 204

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 205

GlaxoSmithKline Enters into Research Agreement with NIAID 206

GlaxoSmithKline Forms Iron Horse Therapeutics with Avalon Ventures 207

GlaxoSmithKline Partners with Merck 208

Pfizer Enters into Agreement with GlaxoSmithKline 209

UC San Francisco Enters into Research Agreement with GlaxoSmithKline 210

MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 211

GlaxoSmithKline Enters into Partnership with Francis Crick Institute 212

University of North Carolina Forms Joint Venture with GlaxoSmithKline 213

Cold Spring Harbor Labs Enters into Co-Development Agreement with GlaxoSmithKline 214

MolMed Enters into Agreement with GlaxoSmithKline 215

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 216

GlaxoSmithKline, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation Enter into Co-Development Agreement 218

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 219

Bioversys Enters into Agreement with GlaxoSmithKline and University of Lille 220

Metabolon Enters Into Agreement With GlaxoSmithKline For Metabolomic Profiling Services 221

GlaxoSmithKline Enters Into Agreement With University of Texas MD Anderson Cancer Center For Immunotherapy Drugs 222

BioRap Enters into Agreement with GlaxoSmithKline 223

GlaxoSmithKline Enters into Partnership with Yale University 224

Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 225

GlaxoSmithKline Forms Joint Venture With Biological E 226

ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 227

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 228

GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 229

GlaxoSmithKline Expands its Partnership with Adimab 230

GlaxoSmithKline Plans To Partner With Chinese Companies 231

GlaxoSmithKline Enters Into Co-Development Agreement With Institute of Chemical Engineering And Sciences 232

Eddingpharm Enters Into Distribution Agreement With GlaxoSmithKline For Tykerb 233

AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 234

Proteologics And GlaxoSmithKline Extend Their Research Agreement 235

Hospital for Sick Children Enters Into Research Agreement With GlaxoSmithKline To Discover Treatment For Cystic Fibrosis 236

Vanderbilt University Enters Into Research Agreement With GlaxoSmithKline For Obesity Drug 237

Priaxon Enters Into Co-Development Agreement With GlaxoSmithKline For Small Molecule Modulators Of PPIs 238

Chroma Therapeutics Expands Co-Development Agreement With GlaxoSmithKline 239

GlycoVaxyn Enters Into Co-Development Agreement With GlaxoSmithKline For Bacterial Vaccines 240

Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 241

GlaxoSmithKline Enters Into Agreement With Imagine Institute To Discover New Drugs For Netherton Syndrome 242

Chiromics Enters Into Drug Discovery Agreement With GlaxoSmithKline 243

Aeras Enters Into R&D Agreement With GlaxoSmithKline Vaccines To Develop Tuberculosis Vaccine 244

GlaxoSmithKline Enters Into Co-Development Agreement With University of Cambridge 245

PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 246

Daiichi Sankyo And GlaxoSmithKline Form Joint Venture In Japan 247

Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 248

Desitin Arzneimittel Enters Into Co-Promotion Agreement With GlaxoSmithKline For Elontril 249

GlaxoSmithKline Enters Into Co-Development Agreement With Yale University 250

Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 251

Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 252

GlaxoSmithKline Enters Into Co-Development Agreement With University of Dundee 253

Angiochem Enters Into Co-Development Agreement With GlaxoSmithKline 254

GlaxoSmithKline Enters Into Agreement With Coland Holdings 255

GlaxoSmithKline Enters Into Co-Development Agreement With Sienna Biotec 256

Eddingpharm Enters Distribution Agreement With GlaxoSmithKline For Relafen 257

Boston Pharma Enters into Licensing Agreement with GlaxoSmithKline 258

GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 259

Zai Lab Enters into Licensing agreement with GlaxoSmithKline 260

GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 261

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 262

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 263

Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 264

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 265

GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 266

Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 267

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 268

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 269

Codexis Enters into Licensing Agreement with GlaxoSmithKline for CodeEvolver Protein Engineering Platform 270

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 272

GlaxoSmithKline Enters into Licensing Agreement with Adaptimmune Therapeutics 273

GlaxoSmithKline Exercises Licensing Agreement with Adaptimmune 274

GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 276

GlaxoSmithKline Enters Into Licensing Agreement With Adimab 277

Immunocore Enters Into Licensing Agreement With GSK For ImmTACs 278

MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 279

GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 281

GlaxoSmithKline Enters Into Licensing Agreement With University of Texas MD Anderson Cancer Center For Antibodies 282

NeRRe Therapeutics Receives Neurokinin Receptor Antagonists from GlaxoSmithKline 283

Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 284

Liquidia Technologies Exercises Option for Licensing Agreement with GlaxoSmithKline 286

GlaxoSmithKline Enters into Licensing Agreement with Pelago Bioscience for CETSA 287

Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 288

Medicines Patent Pool Extends Licensing Agreement with ViiV Healthcare 289

ViiV Healthcare Enters Into Licensing Agreement With Medicines Patent Pool For Epzicom 290

GlaxoSmithKline Enters Into Licensing Agreement With Alacris Theranostics For ModCell System 291

ViiV Healthcare Announces Licensing Agreement For Celsentri 292

GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 293

Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 294

Theravance Biopharma Raises USD23 Million in Private Placement of Shares 296

Amicus Therapeutics Completes Private Placement Of Securities For US Million 297

Theravance Completes Private Placement Of Shares For US3 Million 298

ChemoCentryx Raises USD7 million in Private Placement of Shares 299

GlaxoSmithKline Raises USD1.19 Billion in Public Offering of 1.25% Bonds Due 2026 300

GlaxoSmithKline Raises USD897.1 Million in Public Offering of Bonds Due 2020 301

GlaxoSmithKline Raises USD897.1 Million in Public Offering of 1.75% Bonds Due 2030 302

GlaxoSmithKline Raises USD1.25 Billion in Public Offering of 3.375% Bonds Due 2023 303

GlaxoSmithKline Raises USD0.75 Billion in Public Offering of Bonds Due 2021 304

GlaxoSmithKline Raises USD1.75 Billion in Public Offering of 3.875% Bonds Due 2028 305

GlaxoSmithKline Raises USD1.25 Billion in Public Offering of 3.125% Bonds Due 2021 307

GlaxoSmithKline Raises USD1 Billion in Public Offering of 3.625% Bonds Due 2025 309

GlaxoSmithKline Raises USD832.8 Million in Public Offering of Bonds Due 2026 311

GlaxoSmithKline Raises USD1,428 Million in Public Offering of Bonds Due 2020 312

GlaxoSmithKline Completes Public Offering Of 0.75% Senior Notes Due 2015 For US,000 Million 313

GlaxoSmithKline Completes Public Offering Of 1.5% Senior Notes Due 2017 For US,000 Million 314

GlaxoSmithKline Completes Public Offering Of 2.85% Senior Notes Due 2022 For US,000 Million 315

Dermavant Sciences Acquires Rights of Tapinarof from GlaxoSmithKline for USD331 Million 316

Orchard Therapeutics Acquires Rare Disease Gene Therapy Portfolio from GlaxoSmithKline 317

GlaxoSmithKline Plans to Sell its Ulverston Plant 318

Emergent Biosolutions Acquires Raxibacumab from GSK 319

Avara Pharma to Acquire Consumer Healthcare Manufacturing Facility from GlaxoSmithKline 321

GlaxoSmithKline Plans to Sell its Non-Core brands 322

Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 323

Oncodesign Acquires Francois Hyafil Research Centre from GlaxoSmithKline 324

Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 325

Novartis Pharma Acquires Rights to Ofatumumab for Auto-Immune Indications from GlaxoSmithKline for up to USD1 Billion 326

Almirall Acquires Rights to Veltin and Altabax from Stiefel 327

Interbrands Acquires Europharm from GSK 328

Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 329

Sun Pharma Acquires Opiates Business in Australia from GlaxoSmithKline 330

Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 331

Insulet Acquires Distribution Rights from GlaxoSmithKline 332

Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 333

Roivant Acquires SB742457 from GlaxoSmithKline 335

Dr Reddy's Labs Acquires Habitrol from Novartis Consumer Health 336

Axovant Sciences Acquires Rights to RVT-101 from Glaxo Group and GlaxoSmithKline Intellectual 337

Pernix Therapeutics Completes Acquisition of Treximet Tablets For Migraine From GlaxoSmithKline 338

Suntory Beverage Acquires Lucozade and Ribena Brands from GlaxoSmithKline for USD2.1 Billion 340

Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 342

Aqua Pharma Acquires US Rights To Verdeso Foam From Stiefel 344

Renaissance Acquisition To Acquire Six Dermatology And Three Anti-Viral Products From GSK 345

Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 347

Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For US7 Million 348

Merz Pharma Acquires Onmel From Stiefel Labs 351

Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 352

Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US4 Million 353

Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For US3 Million 355

Prestige Brands Completes Acquisition Of 17 OTC Healthcare Brands From GlaxoSmithKline For US0 Million 357

Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 360

GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 362

GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 364

GlaxoSmithKline Acquires Additional 26% of stake in Glaxo Saudi Arabia 365

MediPal Plans to Acquire 22% Stake in JCR Pharma from Glaxo Group for USD189.7 Million 366

Pacific Biosciences May Sell Itself 367

GlaxoSmithKline Acquires Remaining Stake in GlycoVaxyn for USD190 Million 368

GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 370

AstraZeneca May Acquire Ariad Pharma 371

GlaxoSmithKline Acquires Remaining 30% Stake In Consumer Healthcare Business For US.6 Million 373

GlaxoSmithKline Completes Acquisition Of Additional 24.3% Stake In Indian Arm GlaxoSmithKline Pharma For US.03 Billion 374

GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For US6.5 Million 376

Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 378

GlaxoSmithKline Acquires Okairos For US5 Million 380

GlaxoSmithKline And Avalon Ventures To Invest US5 Million In 10 Drug Discovery Startups 382

GSK Increases Stake In Indian Arm GlaxoSmithKline Consumer Healthcare For US4 Million 383

Takeda America Completes Acquisition Of LigoCyte Pharma For US Million 385

GlaxoSmithKline Acquires Remaining 80.02% Stake In Cellzome, Proteomics Company, For US Million 387

GlaxoSmithKline Completes Acquisition Of Human Genome Sciences For US.6 Billion 389

GlaxoSmithKline Plans To Acquire BioMarin Pharma 392

GlaxoSmithKline Plans To Acquire Turkey-based Pharma Company 393

GlaxoSmithKline Plc, Key Competitors 394

GlaxoSmithKline Plc, Key Employees 395

GlaxoSmithKline Plc, Other Locations 396

GlaxoSmithKline Plc, Subsidiaries 396

GlaxoSmithKline Plc, Joint Venture 409

List Of Figures, Charts and Diagrams
in GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 12-10-2018]

List of Figures

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 18

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 20

GlaxoSmithKline Plc, Medical Devices Deals, 2012 to YTD 2018 22

Additional Details

Publisher

Global Data

Publisher Information

Reference

224563 | GDPH4279D

Number of Pages

501

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
GlaxoSmithKline Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
GlaxoSmithKline K.K. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline K.K. (GSK Japan) a subsidiary of GlaxoSmithKline Plc is a pharmaceutical comp...
10 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline Pharmaceuticals Limited (GSK India) is a pharmaceutical company that manufact...
04 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline plc (GSK) is a healthcare company, which focuses on the development, manufact...
04 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Plc (GSK) - Medical Equipment - Deals and Alliances Profile
SummaryGlaxoSmithKline plc (GSK) is a healthcare company, which focuses on the development, manufact...
24 Feb 2016 by Global Data USD $250 More Info
GlaxoSmithKline Consumer Nigeria PLC (GLAXOSMITH) - Financial and Strategic SWOT Analysis Review
SummaryGlaxoSmithKline Consumer Nigeria PLC (GlaxoSmithKline Consumer Nigeria) a subsidiary of Glaxo...
09 Jan 2016 by Global Data USD $300 More Info
GlaxoSmithKline Consumer Nigeria PLC (GLAXOSMITH) - Financial and Strategic SWOT Analysis Review
SummaryGlaxoSmithKline Consumer Nigeria PLC (GlaxoSmithKline Consumer Nigeria) a subsidiary of Glaxo...
08 Nov 2015 by Global Data USD $300 More Info
Physician Views: Is GlaxoSmithKline's BRAF/MEK combo making headway in V600 mutation-positive melanoma patients?
Scope Although the clinical promise of cancer immunotherapies looks poised to see these products gai...
22 Jul 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Assessing the launch of GlaxoSmithKline's Breo Ellipta
Scope It remains early in the launch, but available evidence suggests that GlaxoSmithKline's Breo El...
21 Jan 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
01 Aug 2013 by FirstWord Pharma USD $695 More Info

This report is published by Global Data

Download Free Report Summary PDF

GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 12-10-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)